Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma

Table 6 Relationships between the prognostic (± relapses) and the mRNA levels of the seven selected genes in 97 estrogen receptor alpha-positive breast tumors

Gene	Tumors without relapses (n = 65)	Tumors with relapses (n = 32)	P ^a	ROC–AUC^b
CYP2A6	1.2 (0.001–9741.1)^c	0.8 (0.01–7228.8)	NS (0.17)	0.41 (0.29–0.54)^d
CYP2B6	56.1 (0.3–1053.1)	14.7 (0.03–249.8)	0.011	0.34 (0.23–0.45)
FMO5	3.9 (0.2–30.1)	1.4 (0.1–23.9)	0.0016	0.30 (0.19–0.41)
GSTM3	2.1 (0.07–12.2)	1.7 (0.09–21.2)	NS (0.80)	0.48 (0.35–0.62)
SULT2B1	4.9 (0.2–84.4)	3.5 (0.4–21.0)	NS (0.65)	0.47 (0.35–0.59)
NAT1	35.9 (1.6–295.6)	10.0 (1.1–134.1)	0.000047	0.24 (0.14–0.35)
ABCC11	15.9 (0.06–195.5)	16.6 (0.04–461.7)	NS (0.60)	0.46 (0.33–0.60)

^a P value, Mann–Whitney test; NS, not significant. ^b Receiver–operating characteristics (ROC)–area under curve (AUC) analysis. ^c Median (range) of gene mRNA levels. ^d AUC value (95% confidence interval).

ISSN: 1465-542X